Navigation Links
Onyx Pharmaceuticals Announces First Quarter 2011 Financial Results Teleconference and Webcast
Date:4/21/2011

SAN FRANCISCO, April 21, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host a webcast and teleconference with management to discuss first quarter 2011 financial results, as well as provide a general business overview on Wednesday, May 4, 2011, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time; 2:00 p.m. Central European Time).  Financial results for the first quarter ended March 31, 2011 will be released earlier that day.

Interested parties may access a live webcast of the presentation on the company's website at: http://www.onyx-pharm.com/investors/event-calendarWithin the U.S.:

888-771-4371International:

847-585-4405Passcode:

29609004#A replay of the presentation will be available on the Onyx website or by dialing:Dial in:

630-652-3042 Passcode:

29609004# (approximately one hour after the teleconference concludes)  The replay will be available through May 18, 2011. About Onyx Pharmaceuticals, Inc.Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a selective proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma in various settings and solid tumors. ONX 0801,
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2011 Financial Results
2. Fleming Pharmaceuticals Now Ready to Step Up Production of Nuclear Radiation Safeguard, ThyroShield®
3. Marinus Pharmaceuticals Announces Commencement of Phase 2 Trial of Ganaxolone for the Treatment of Posttraumatic Stress Disorder
4. Hanmi Pharmaceuticals to Acquire the Rights for a Promising Phase II Anti-cancer Src Kinase/Pretubulin Dual Inhibitor from Kinex Pharmaceuticals, in Selected Asian Territories
5. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
6. Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 36th Annual Health Care Conference
8. Sagent Pharmaceuticals Upsizes and Prices Initial Public Offering
9. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
10. Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection
11. Bexion Pharmaceuticals Receives Outstanding Biotech Innovation Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014 Reportlinker.com announces that a ... its catalogue: Wireless Opportunities in ... UWB WWAN, WMAN, WLAN and other technologies) ... Kalorama Information,s Wireless Opportunities in Healthcare ... WWAN, WMAN, WLAN and other technologies) is ...
(Date:8/20/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), ... that its VENTANA System for Primary Diagnosis 1 ... Union for routine pathology, including primary diagnosis with ... Virtuoso software coupled with either the VENTANA iScan ... provides automated digital slide creation, case management and ...
(Date:8/20/2014)... 2014  Decision Resources Group finds that ... device market will expand through 2023 as ... fibrillation (AF). The increasing acceptance of ablation ... will spur adoption of premium-priced products designed ... loop diagnostic catheters, cryoablation catheters and contact ...
Breaking Medicine Technology:Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 2Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 3Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 4Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 5Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 6Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 7Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 8Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 9Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 10Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 11Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 12Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 13Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 14Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 15Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 16Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3
... 30, 2011 /PRNewswire-iReach/ -- CoLucid Pharmaceuticals, ... that it has raised $7.5 million of a ... existing investors to support further late stage development ... Ventures, Domain Associates, Care Capital, Pearl Street Venture ...
... Biopharma, Inc. (OTC.BB: GNBP), a biotechnology company developing targeted ... Shareholders will be posted today to the investor relations ...  In addition, on August 22, 2011, the Company filed ... Report for the three and six months ended June ...
Cached Medicine Technology:CoLucid Pharmaceuticals Raises $7.5 Million of Planned $9.5 Million 2Genesis Biopharma Announces Letter to Shareholders Posted to Website 2Genesis Biopharma Announces Letter to Shareholders Posted to Website 3Genesis Biopharma Announces Letter to Shareholders Posted to Website 4Genesis Biopharma Announces Letter to Shareholders Posted to Website 5
(Date:8/20/2014)... through fast-moving waters may be at risk, suggests new ... salmon encounter turbulent, fast-moving water such as rapids ... upstream using a behaviour known as "burst swimming" that ... sockeye passed through extremely fast-moving water, we started to ... spawning grounds," said Nicholas Burnett, a research biologist at ...
(Date:8/20/2014)... common cause of endophthalmitis, a potentially blinding condition that ... injections, are the well-known staphylococci ("staph") and ... study published in the August issue of Ophthalmology ... of cases at New York Eye and Ear Infirmary ... found that gram-positive bacteria, which include staph and strep ...
(Date:8/20/2014)... By Steven Reinberg ... -- A rare birth disorder that dismantles a baby,s immune ... study of more than 3 million infants says. This ... for the life-threatening but treatable condition known as severe combined ... "People were made aware of this condition by the boy ...
(Date:8/20/2014)... 20, 2014 Get the report here: ... mergermarket presents “Deal Drivers 2014 Half Year Report for ... M&A activity in both North and South America, with ... About Merrill DataSite     , Merrill DataSite is a ... the due diligence process by providing a highly efficient ...
(Date:8/20/2014)... owners looking for ways to make smart changes – and ... check out the latest blog post from Per Wickstrom on ... blog post, which is entitled “Small Changes that Can Have ... , Opportunities for making minor improvements abound, but many ... alert and focused. , Changes shouldn’t be based ...
Breaking Medicine News(10 mins):Health News:Salmon forced to 'sprint' less likely to survive migration 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 3Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3Health News:Register to Download Merrill DataSite's Report: Deal Drivers 2014 Half Year Report for the Americas 2Health News:Per Wickstrom’s Latest Blog Post Focuses on Small Changes that Can Have a Big Impact on Business 2
... - including Parkinson's, Alzheimer's, Diffuse Lewy body disease, ... synucleinopathies. Most commonly they become symptomatic due to ... the case of Parkinson's it is dopamine. When ... become impaired, which occurs with oxidation, the eventual ...
... men over the age of 40 years and is the ... goes undetected till it is advanced and beyond cure. However ... and now men over the age of 40 years can ... the most promising "tumour markers" in medicine was developed over ...
... Paul Greengard and Eric Kandel won the Nobel ... transduction in the nervous system." The three Nobel ... prize for their pioneering discoveries "concerning one type ... as slow synaptic transmission," according to the award ...
... that more than two-thirds of births in Russia are marred ... clinic is suffering health problems. , ,The number of ... 30 percent last year, said Olga Frolova, head of the ... that the decline is due to the spread of heavy ...
... drug could make millions of people suffering from ... Disease (COPD) or smoker’s lung, is an irreversible progressive ... emphysema and chronic bronchitis. In tests involving 500 people ... decade, the drug appeared to be safer and better ...
... Researchers at the University of Texas Health Science Center at ... dish from single mouse cells - and they think humans ... direction where they could take ,initial tissue from a [human] ... tooth for them.To accomplish this seemingly futuristic feat, researchers need ...
Cached Medicine News:
... the best EMR value for many medical ... Charting Plus™ relies heavily on a user-friendly ... improve documentation quality and increase productivity in ... specific to your medical specialty. Each program ...
... The Frontier device is a ... with one atrial and two ... chronic atrial fibrillation (AF) who ... ablation and who have NYHA ...
Intrinsic Dual Chamber ICD With MVP Mode (Managed Ventricular Pacing). MVP promotes intrinsic conduction and is clinically proven to reduce unnecessary right ventricular (RV) pacing to approximately...
Provides the security of suture and ease of automated knot tying for vascular closure of 5-8F....
Medicine Products: